Ignite Creation Date:
2024-05-06 @ 3:09 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02213744
Status:
TERMINATED
Last Update Posted:
2017-01-06
First Post:
2014-08-06
Brief Title:
MM-302 Plus Trastuzumab vs Chemotherapy of Physicians Choice Plus Trastuzumab in HER2-Positive Locally AdvancedMetastatic Breast Cancer Patients
Sponsor:
Organization:
Merrimack Pharmaceuticals
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
113
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: